Guggenheim Capital’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$721K Sell
3,214
-374
-10% -$93.2K 0.01% 1092
2025
Q4
$864K Sell
3,588
-1,586
-31% -$406K 0.01% 1015
2025
Q3
$1.42M Sell
5,174
-11
-0.2% -$3K 0.01% 806
2025
Q2
$1.34M Buy
5,185
+93
+2% +$22.2K 0.01% 788
2025
Q1
$1.14M Sell
5,092
-940
-16% -$219K 0.01% 834
2024
Q4
$1.38M Buy
6,032
+2,056
+52% +$495K 0.01% 779
2024
Q3
$971K Sell
3,976
-2,728
-41% -$610K 0.01% 1120
2024
Q2
$1.28M Sell
6,704
-2,456
-27% -$498K 0.01% 993
2024
Q1
$1.81M Sell
9,160
-156
-2% -$28.6K 0.01% 920
2023
Q4
$1.6M Sell
9,316
-241
-3% -$37K 0.01% 939
2023
Q3
$1.41M Sell
9,557
-2,153
-18% -$389K 0.01% 949
2023
Q2
$2.56M Sell
11,710
-999
-8% -$223K 0.02% 755
2023
Q1
$2.78M Buy
12,709
+1,752
+16% +$380K 0.02% 738
2022
Q4
$2.28M Sell
10,957
-886
-7% -$195K 0.02% 810
2022
Q3
$2.58M Buy
11,843
+1,568
+15% +$357K 0.02% 746
2022
Q2
$2.15M Sell
10,275
-5,155
-33% -$1.1M 0.02% 863
2022
Q1
$3.74M Sell
15,430
-1,759
-10% -$425K 0.02% 768
2021
Q4
$4.48M Sell
17,189
-340
-2% -$88.2K 0.02% 727
2021
Q3
$4.62M Sell
17,529
-1,156
-6% -$316K 0.03% 689
2021
Q2
$4.61M Buy
18,685
+2,238
+14% +$470K 0.03% 709
2021
Q1
$3.19M Buy
16,447
+1,815
+12% +$364K 0.02% 811
2020
Q4
$3.11M Buy
14,632
+2,692
+23% +$537K 0.02% 775
2020
Q3
$2.05M Sell
11,940
-8,507
-42% -$1.57M 0.01% 880
2020
Q2
$3.92M Buy
20,447
+7,721
+61% +$1.26M 0.03% 615
2020
Q1
$1.87M Sell
12,726
-4,080
-24% -$650K 0.02% 815
2019
Q4
$2.6M Buy
16,806
+5,277
+46% +$761K 0.02% 931
2019
Q3
$1.56M Sell
11,529
-2,072
-15% -$271K 0.01% 1113
2019
Q2
$1.66M Sell
13,601
-3,889
-22% -$431K 0.01% 1132
2019
Q1
$1.82M Sell
17,490
-5,813
-25% -$600K 0.01% 1115
2018
Q4
$2.65M Sell
23,303
-21,387
-48% -$2.29M 0.02% 903
2018
Q3
$5.16M Sell
44,690
-4,677
-9% -$512K 0.03% 706
2018
Q2
$5.11M Sell
49,367
-588,407
-92% -$59.5M 0.03% 707
2018
Q1
$62.8M Sell
637,774
-84,706
-12% -$8M 0.15% 189
2017
Q4
$61.2M Buy
722,480
+229,030
+46% +$18.9M 0.14% 215
2017
Q3
$38M Buy
493,450
+474,342
+2,482% +$36.3M 0.09% 435
2017
Q2
$1.49M Sell
19,108
-529
-3% -$37.8K ﹤0.01% 1836
2017
Q1
$1.42M Sell
19,637
-11,608
-37% -$802K ﹤0.01% 1894
2016
Q4
$1.94M Sell
31,245
-5,525
-15% -$338K 0.01% 1707
2016
Q3
$2.38M Buy
36,770
+8,366
+29% +$557K 0.01% 1504
2016
Q2
$1.8M Sell
28,404
-7,795
-22% -$460K 0.01% 1632
2016
Q1
$2.09M Sell
36,199
-1,051
-3% -$59.5K 0.01% 1541
2015
Q4
$2M Sell
37,250
-12,489
-25% -$704K 0.01% 1609
2015
Q3
$2.54M Sell
49,739
-8,378
-14% -$451K 0.01% 1425
2015
Q2
$3.28M Buy
58,117
+13,390
+30% +$845K 0.01% 1396
2015
Q1
$3.21M Sell
44,727
-10,991
-20% -$714K 0.01% 1420
2014
Q4
$3.12M Buy
55,718
+21,280
+62% +$1.11M 0.01% 1405
2014
Q3
$1.7M Buy
34,438
+1,653
+5% +$84.2K ﹤0.01% 1890
2014
Q2
$1.66M Sell
32,785
-12,284
-27% -$609K ﹤0.01% 1956
2014
Q1
$2.02M Sell
45,069
-2,195
-5% -$98.6K 0.01% 1796
2013
Q4
$2.23M Sell
47,264
-222,933
-83% -$11.3M 0.01% 1693
2013
Q3
$14.3M Buy
270,197
+12,511
+5% +$607K 0.05% 667
2013
Q2
$11.6M Buy
+257,686
New +$12.2M 0.05% 698

Other funds holding RMD

Guggenheim Capital's RMD Position: Q1 2026 in Review

Guggenheim Capital reduced its ResMed (RMD) stake by 10% in Q1 2026, selling an estimated $93.2K and leaving 3,214 shares worth $721K. The position accounts for 0.01% of the portfolio, ranked #1092.

Guggenheim Capital first reported a position in RMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $62.8M in Q1 2018. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Guggenheim Capital held 3,214 shares of ResMed worth $721K as of Q1 2026.
  • Guggenheim Capital sold 374 ResMed shares in Q1 2026, an estimated $93.2K.
  • ResMed made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1092 holding.
  • Guggenheim Capital first reported a position in ResMed in Q2 2013 and has held it in 52 quarters since.
  • Guggenheim Capital's ResMed position peaked at $62.8M in Q1 2018.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.